Legal uncertainties frustrate biotechnology support for agric – NEXT
By Dr. Matthew Watson
 Bikya Masr | Legal uncertainties frustrate biotechnology support for agric NEXT Modern biotechnology has the potential to address these concerns and guarantee food security in the country, especially as there is recognisable need to improve the productive capacity of rural farmers through the deployment of appropriate technologies ... India offers Nigerians biotechnology scholarshipsBikya Masr |
Uncategorized
Comments Off on Legal uncertainties frustrate biotechnology support for agric – NEXT |
July 31st, 2011
Clinical trial costs
By Dr. Matthew Watson
Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)
Average per-patient trial costs across all therapeutic areas:
Phase I: $21,883
Phase II: $36,070
Phase IIIa: $47,523
Phase IIIb: $47,095
Phase IV: $17,042
Average cost per patient for a cardiovascular trial:
Phase II: $33,700
Phase IIIa: $21,750
Phase IIIb: $6,830
In oncology, the average per patient trial cost:
Phase II: $73,303
Phase IIIa: $57,207
Phase IIIb: $65,900
For central nervous system disorders:
Phase II: $28,197
Phase IIIa: $33,768
Phase IIIb: $41,824
For diabetes:
Phase II: $ 8,854
Phase IIIa: $12,667
Phase IIIb: $10,700
Anyone have any thoughts or data as to how this compares to cell therapy trials?
--Lee
*survey conducted by Cutting Edge Information.
International Stem Cell Corporation to Hold Business Update Conference Call on August 10
By Dr. Matthew Watson
International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.
Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site athttp://www.intlstemcell.com.
A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com
Stem Cell Therapy
Comments Off on International Stem Cell Corporation to Hold Business Update Conference Call on August 10 |
July 31st, 2011
Merck strategist focuses on putting the pieces together – The Star-Ledger – NJ.com
By Dr. Matthew Watson
The Star-Ledger - NJ.com | Merck strategist focuses on putting the pieces together The Star-Ledger - NJ.com During the years he spent overseeing Merck's licensing efforts, Turner left his signature on more than 300 deals, most of them with small biotechnology companies whose products held the promise of building Merck's drug business. ... |
Uncategorized
Comments Off on Merck strategist focuses on putting the pieces together – The Star-Ledger – NJ.com |
July 31st, 2011
The potential of stem cells
By Sykes24Tracey
Stem cells can be thought of as "master" cells. You've probably heard about the controversy of embryonic stem cells in the news
More:
The New World of Medicine: Stem Cell Therapy
By NEVAGiles23
In this video I will lay out my thinking as to why stem cell therapy is the next boom; it will in fact, change the world. What do you think?
More here:
Uncategorized
Comments Off on The New World of Medicine: Stem Cell Therapy |
July 27th, 2011
Lou Gehrig’s Disease (ALS): Stem Cell Therapy – A Patient’s Perspective
By Dr. Matthew Watson
(Part 7 of 8) Dan Desmond, spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Desmond has a Master of Arts in counseling psychology and is founding director of Family Focus Christian Counseling, Inc
Go here to read the rest:
Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective
Uncategorized
Comments Off on Lou Gehrig’s Disease (ALS): Stem Cell Therapy – A Patient’s Perspective |
July 26th, 2011
Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami)
By raymumme
Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined
See more here:
Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami)
Uncategorized
Comments Off on Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami) |
July 26th, 2011
Meditation May Help Women Cope With Hot Flashes
By Dr. Matthew Watson
(HealthDay News) -- An easy-to-learn meditation technique can help ease the hot flashes, night sweats and insomnia of menopause, a new study says.
The University of Massachusetts research showed that mindfulness training, based on a Buddhist meditation concept, reduced the distress associated with hot flashes and improved physical, psychosocial and sexual functioning.
"The findings are important because hormone replacement therapy, used to treat menopause symptoms in the past, has been associated with health risks," said study author James Carmody, an associate professor of medicine in the division of preventive and behavioral medicine.
About 40 percent of menopausal women suffer from hot flashes and night sweats, which undermine their quality of life, the researchers noted. But since hormone replacement therapy has been linked with an increased risk of heart disease, breast cancer and stroke, Carmody observed that "not only are women looking for alternative treatments, it is an NIH (National Institutes of Health) priority to find behavioral treatments Read more...
Cardiofy Heart Care Supplement
Integrative Medicine
Comments Off on Meditation May Help Women Cope With Hot Flashes |
July 24th, 2011
Comic-Con 2011: IN TIME shows promise with new trailer – Gordon and the Whale
By Dr. Matthew Watson
 USA Today | Comic-Con 2011: IN TIME shows promise with new trailer Gordon and the Whale IN TIME is an action/thriller and the child of GATTACA, the genetic engineering has just gotten better. In this world, you stop aging at 25 and then only have 1 year left unless you can buy, trade, or steal more. The rich can live forever, ... Comic-Con Interview: Andrew Niccol on Social Commentary, Ruining Film for ...Film School Rejects Comic-Con 2011: In Time Coverage and PanelUGO |
Uncategorized
Comments Off on Comic-Con 2011: IN TIME shows promise with new trailer – Gordon and the Whale |
July 24th, 2011
Biotechnology Bounces Back With 46% Rise in Venture Capital – San Francisco Chronicle
By Dr. Matthew Watson
 Citybizlist (press release) | Biotechnology Bounces Back With 46% Rise in Venture Capital San Francisco Chronicle July 20 (Bloomberg) -- Venture-capital funding in biotechnology companies jumped 46 percent in the second quarter, as investors looked to replenish their portfolios after an increase in acquisitions and initial public offerings. ... Biotech sees jump in VC fundingSan Francisco Business Times (blog) Venture Capital Investments Rise 19% In Q2 2011 To $7.5 Billion In 966 DealsPR Web (press release) Venture capitalists invest $13.75 million in South Carolina in second quarterCharleston Regional Business CNET all 145 news articles » |
Uncategorized
Comments Off on Biotechnology Bounces Back With 46% Rise in Venture Capital – San Francisco Chronicle |
July 24th, 2011
Pakistan can emerge as biotechnology leader – Pakistan Observer
By Dr. Matthew Watson
 The Express Tribune | Pakistan can emerge as biotechnology leader Pakistan Observer Lahore—Provincial Minister for Agriculture, Malik Ahmad Ali Aulakh has said that 21 century is the century of Biotechnology and Pakistan has tremendous potential to emerge as Biotechnology leader. Speaking at a seminar on Bio-technology at Lahore ... 21st century belongs to biotechnologyThe Nation, Pakistan Biotechnology: 'Pakistan has potential to be world leader'The Express Tribune |
Uncategorized
Comments Off on Pakistan can emerge as biotechnology leader – Pakistan Observer |
July 24th, 2011
New Report Details Uphill Battle to Solve the U.S.’s Pain Problem
By Dr. Matthew Watson
Chronic pain affects at least one in three adults in the U.S., which is more than the sum total of those with heart disease, cancer and diabetes combined. For many of these 116 million Americans, their pain is severe and eludes available treatments. In addition to the human suffering, the monetary cost of medical treatment and lost productivity has reached $635 billion a year. [More]
Uncategorized
Comments Off on New Report Details Uphill Battle to Solve the U.S.’s Pain Problem |
July 24th, 2011
The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper
By Dr. Matthew Watson
International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office. ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Stem Cell Therapy
Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper |
July 24th, 2011
International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells
By Dr. Matthew Watson
CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.
The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).
ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body.
However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.
Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #
Stem Cell Therapy
Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells |
July 24th, 2011
Post Stem Cell Therapy Video for Cerebral Palsy
By JoanneRUSSELL25
Stem Cell Therapy for Cerebral Palsy done at Neurogen Brain and Spine Institute Pvt. Ltd.
The rest is here:
Post Stem Cell Therapy Video for Cerebral Palsy
Uncategorized
Comments Off on Post Stem Cell Therapy Video for Cerebral Palsy |
July 21st, 2011
Duffy Gets Stem Cell Therapy
By Dr. Matthew Watson
Kingsbury Animal Hospital in St. Louis performs it's first stem cell procedure on Duffy, a 10 year old Lab who suffers from arthritis.
Follow this link:
Duffy Gets Stem Cell Therapy
Uncategorized
Comments Off on Duffy Gets Stem Cell Therapy |
July 20th, 2011
Bone Marrow Stem Cell Donation
By Dr. Matthew Watson
In August 2009 I donated Bone Marrow Stem Cells via the apheresis procedure. I have been registered with the Australian Bone Marrow Donor Registry since 2001.
Follow this link:
Lou Gehrig’s Disease (ALS): UCSD Team’s Stem Cell Therapy Rationale
By raymumme
(Part 3 of 8) Don Cleveland, Ph.D. spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010
Read this article:
Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale
Uncategorized
Comments Off on Lou Gehrig’s Disease (ALS): UCSD Team’s Stem Cell Therapy Rationale |
July 19th, 2011
From Surgical Repair to Stem Cell Repair: A Surgeon’s Journey by Leonard Smith MD, FACS
By daniellenierenberg
Dr. Smith focuses on understanding the natural process of how the body uses tissue stem cells and bone marrow stem cells, what people can do to facilitate or inhibit this natural process and how science can help us manage disease or aging with autologous or allogenic stem cell therapy.
View original post here:
From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS
Bone Marrow Stem Cells
Comments Off on From Surgical Repair to Stem Cell Repair: A Surgeon’s Journey by Leonard Smith MD, FACS |
July 19th, 2011